Malaria eradication remains an elusive goal despite progress in controlling the disease, requiring multiple activities, interventions, and approaches. Scientists must adapt their strategies to address changing parasite behavior and distribution, developing new tools and interventions to keep ahead of emerging challenges.
A Phase II clinical study found that a vaccine candidate can cause a modest but sustained reduction in genital and gastrointestinal GBS bacterial colonization. The vaccine was also found to be safe and well-tolerated, eliciting a strong immune response.
Researchers found that high-affinity mutant viruses alternate with low-affinity forms in antigenic drift. Increasing child vaccination could slow this process and extend seasonal influenza vaccine effectiveness.
The National Institutes of Health is launching a clinical trial to find the ideal dose of the 2009 H1N1 influenza vaccine for individuals with severe asthma. The study aims to assess the immune response and safety of two different doses of the vaccine in participants with mild, moderate, or severe asthma.
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting clinical trials to test the safety and efficacy of the 2009 H1N1 influenza vaccine in HIV-infected pregnant women and children, youth. The trials aim to determine whether higher doses of the vaccine can elicit a protective immune response in these populations.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded contracts to discover novel vaccine adjuvants. The goal is to enhance the immune response and extend vaccine supply. Researchers will test new compounds in animal models and human cells.
Researchers analyzed decades-old frozen infant stool samples to understand norovirus evolution. The study reveals that the GII.4 genotype emerged years before its recent identification as a cause of severe global outbreaks.
Researchers discovered a genetic mutation in the DOCK8 gene that accounts for combined immunodeficiency, a previously undefined primary immune deficiency disease. This discovery provides a more accurate diagnosis for individuals with this rare condition and sheds light on its causes.
A US-led clinical trial in Thailand has found that an investigational vaccine regimen reduced the risk of HIV infection by 31% among vaccinated participants. The study, which enrolled over 16,000 adults, suggests a promising approach to preventing HIV transmission.
A large study found pulmonary NTM disease increasing significantly in men and women in Florida and New York, with no changes in California. The disease is more common among women, particularly in the fifth or sixth decade of life.
Preliminary analysis of blood samples from trial participants suggests that the 2009 H1N1 influenza vaccine generates an immune response that is expected to be protective against the virus in most children between 10-17 years old. Younger children had a less robust early response to the vaccine.
A large-scale clinical trial, VOICE, is testing the safety and efficacy of an antiretroviral microbicide gel and pre-exposure prophylaxis (PrEP) regimen to prevent HIV infection in women in four African countries. The study aims to determine which intervention is more effective and acceptable to participants.
The 2009 H1N1 influenza vaccines have demonstrated a strong immune response in most healthy adults when administered in a single dose, with robust protection observed in both younger and older adults. The early data from clinical trials indicate that the vaccines are well-tolerated.
The NIAID is conducting a trial to test the safety and efficacy of a 2009 H1N1 influenza vaccine in pregnant women. The trial aims to provide critical information for public health planning, as pregnant women are at higher risk of developing severe illness from the flu virus.
The National Institute of Allergy and Infectious Diseases (NIAID) has launched two new clinical trials to investigate the optimal use of antimicrobial drugs in various clinical settings. The trials aim to determine if shorter treatment durations can be effective while reducing the risk of bacterial resistance.
Researchers found that levels of the 2009 H1N1 virus rose more quickly than seasonal flu strains, causing more severe disease. The novel virus was also transmitted more easily from infected to uninfected ferrets.
The new initiative will characterize the human immune system under normal conditions and following infection or vaccination, using systems biology approaches. Researchers will analyze human samples from well-characterized cohorts to identify specific patterns of immune molecules that reflect immune system function.
The NIAID analysis of 14 global influenza epidemics reveals no consistent pattern of wave-like surges prior to major outbreaks. Instead, the authors note a great diversity of severity among past pandemics, making predicting the future course of H1N1 virus difficult.
Scientists at Stanford University have identified a gene variant that may play a role in the development of type 1 diabetes. The study found that cells in the pancreatic lymph nodes produce two forms of the Deaf1 gene, one functional and one nonfunctional. Increased levels of the nonfunctional variant were found in people with type 1 d...
Researchers found no significant correlations between laboratory test measurements and asthma exacerbations among study participants. A large, longitudinal study provided the most comprehensive analysis to date of factors thought to be useful in predicting asthma attacks.
Research reveals that even after successful treatment with acyclovir, genital herpes sores create an environment conducive to HIV infection. The study found high concentrations of specific immune cells at the site of lesions, increasing the risk of HIV transmission.
Researchers found a potent staph toxin responsible for disease severity and its connection to antibiotic resistance. The study identified the gene encoding the toxin, which is transmitted through horizontal gene transfer.
A study on cynomolgus macaques exposed to chronic wasting disease (CWD) shows that they remain healthy after over six years of observation. The findings suggest a potential species barrier against CWD in humans, but more research is needed to confirm this.
The National Institute of Allergy and Infectious Diseases (NIAID) will conduct a series of clinical trials to test two candidate H1N1 flu vaccines. The trials will evaluate the safety and ability to induce protective immune responses in healthy adults and elderly individuals.
The genomes of two parasitic flatworm species causing schistosomiasis have been sequenced, revealing potential drug targets and enzymes that can be targeted with drugs. The research may lead to new treatments for the debilitating disease.
The 1918 influenza pandemic created a viral dynasty that persists to this day, with all human-adapted influenza A viruses being descendents of the founding virus. The novel 2009 H1N1 virus is yet another manifestation of this enduring viral family.
Nearly half of the world's population is at risk of malarial infection, causing over 250 million clinical episodes and one million deaths each year. Researchers identified key challenges in developing a protective malaria vaccine, including identifying which proteins provoke a strong immune response.
Researchers suggest a promising approach to create an antibody-based HIV vaccine by leveraging naturally occurring broadly neutralizing antibodies. By understanding how these antibodies evolve and persist, scientists aim to develop a vaccine that can prime the body to make protective antibodies before exposure to HIV.
Top HIV/AIDS researchers at NIAID outline a test-and-treat strategy that could reduce HIV incidence by 90% within 10 years. The proposal also involves pre-exposure prophylaxis, latent virus control, and improved prevention strategies.
A new clinical trial found that starting antiretroviral therapy (ART) before CD4+ T cell counts drop below 200 cells/mm3 improves survival for HIV-infected adults. The study's results have the potential to change standard of care for HIV infection in dozens of countries.
The National Institute of Allergy and Infectious Diseases has renewed funding for the 11 Regional Centers of Excellence, with a total of $455 million over five years. The centers will focus on developing countermeasures against emerging infectious diseases.
Researchers developed a mathematical model to predict immune responses to influenza A viruses, including novel strains like H1N1. The model suggests that prolonged infection limits T cell production and antigen presentation, making antiviral therapy most effective within two days after infection.
The Multicenter AIDS Cohort Study (MACS) has significantly contributed to the scientific understanding of HIV/AIDS through its 25 years of behavioral and biological data. Key findings include identifying unique features of long-term non-progressors, managing HIV treatment, and the link between viral load and progression of HIV disease.
The NIAID and Chinese officials have signed an agreement to develop a collaborative TB research program at the Henan Provincial Chest Hospital. Researchers will focus on clinical trials of new drugs or drug combinations for MDR and XDR TB treatment. The goal is to improve diagnosis and treatment methods for this devastating disease.
Researchers have identified cellular components in mosquitoes and humans that the dengue virus uses to multiply, paving the way for potential treatments. The study found 116 host factors, including 42 with human counterparts, which may serve as targets for new drugs.
The new guidelines outline advances in diagnostic tests, treatments, and preventive care for HIV-infected individuals. Effective antiretroviral therapy is crucial in preventing and managing opportunistic infections.
Scientists have identified a new role for lung epithelial cells in detecting airborne antigens and triggering allergic responses. The discovery suggests that targeting Toll-like receptors may lead to novel treatments for asthma and other allergic diseases.
A study found that medically supervised male circumcision significantly reduces the risk of acquiring genital herpes (HSV-2) and human papillomavirus (HPV), but has no effect on syphilis. Circumcision was also associated with a 28% lower risk of HSV-2 infection and a 35% reduced prevalence of HPV.
A new experimental vaccine has shown promising results in preventing cytomegalovirus (CMV) infection in infants, reducing the risk by 50% compared to a saline injection. The vaccine was given to 441 CMV-negative women and found to be safe with minimal side effects.
Researchers found that USA300 and its forefather USA500 are nearly identical in virulence and have similar levels of virulence gene production. They also discovered that alpha toxin and alpha-type phenol-soluble modulins play a crucial role in determining the severity of community-associated MRSA infection.
Scientists have developed a new technology to isolate dozens of HIV-specific antibodies from a single individual, allowing for the first time to study natural antibody-mediated HIV neutralization. This breakthrough may prove important in understanding how effective HIV-neutralizing antibodies arise during infection.
Scientists have found that combining FDA-approved drugs meropenem and clavulanate is effective in killing laboratory-grown strains of Mtb, the bacterium that causes tuberculosis. This breakthrough could lead to a new treatment option for people infected with XDR TB, a rare but deadly form of multidrug-resistant TB.
A recent study has identified a common attachment site on influenza A virus subtypes that can be targeted to develop a universal flu vaccine. This breakthrough discovery was made by researchers at The Scripps Research Institute and provides a blueprint for the development of new antiviral drugs.
Researchers identified human monoclonal antibodies that can neutralize a broad range of influenza A viruses, including seasonal and pandemic flu strains. These antibodies offer potential for treatment and prevention of the flu during outbreaks or pandemics.
Two large clinical trials found that IL-2 immunotherapy increases CD4+ T cell counts in HIV-infected individuals on antiretroviral therapy, but fails to reduce the risk of opportunistic diseases or death. The treatment's efficacy was not linked to better health outcomes.
A new mathematical model predicts that pre-exposure prophylaxis (PrEP) could substantially reduce the lifetime risk of HIV infection, but its cost-effectiveness varies depending on target population and drug costs. With modest improvements, PrEP might be as effective as other public health interventions.
A recent clinical trial found that the investigational vaginal gel PRO 2000 showed encouraging signs of success, with a 30% effectiveness rate in preventing HIV infection. The Phase II/IIb trial enrolled over 3,000 women and tested two candidate microbicides, one of which boosted the natural acidity of the vagina to inactivate pathogens.
A new study reveals that the chemical mediator sphingosine-1-phosphate plays a crucial role in maintaining bone balance. Researchers found that mice with functional S1P receptors had denser bones than those without, suggesting a potential target for treating bone-resorptive disorders.
Martin Delaney, founder of Project Inform, received the NIAID Director's Special Recognition Award for his efforts on behalf of HIV-infected people. He played a key role in expanding access to life-saving antiretroviral medications.
A new mouse model for peanut allergy has been developed by Chicago researchers, mimicking symptoms of a human allergic reaction to peanuts. The model uses a mixture of whole peanut extract and staphylococcal enterotoxin B to stimulate an immune response, producing severe symptoms similar to those found in human anaphylaxis.